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Abstract 
Background: Breast conserving surgery (BCS) plus external beam radiotherapy (EBRT) is considered the standard treatment for early 
breast cancer. We have investigated the possibility of irradiating the residual gland, using an innovative nuclear medicine approach 
named IART
® (Intra-operative Avidination for Radionuclide Therapy). 
Aim: The objective of this study was to determine the optimal dose of avidin with a fixed activity (3.7 GBq) of 
90Y-biotin, in order to 
provide a boost of 20 Gy, followed by EBRT to the whole breast (WB) at the reduced dose of 40 Gy. Local and systemic toxicity, patient’s 
quality of life, including the cosmetic results after the combined treatment with IART
® and EBRT, were assessed. 
Methods: After tumour excision, the surgeon injected native avidin diluted in 30 ml of saline solution into and around the tumour bed (see 
video). Patients received one of three avidin dose levels: 50 mg (10 pts), 100 mg (15 pts) and 150 mg (10 pts). Between 12 to 24 h after 
surgery, 3.7 GBq 
90Y-biotin spiked with 185 MBq 
111In-biotin was administered intravenously (i.v.). Whole body scans and SPECT images 
were performed up to 30 h  post-injection for dosimetric purposes. WB-EBRT was administered four weeks after the IART
® boost. Local 
toxicity and quality of life were evaluated. 
Results: Thirty-five patients were evaluated. No side effects were observed after avidin administration and 
90Y-biotin infusion. An avidin 
dose level of 100 mg resulted the most appropriate in order to deliver the required radiation dose (19.5 + 4.0 Gy) to the surgical bed.  At 
the end of IART
®, no local toxicity occurred and the overall cosmetic result was good. The tolerance to the reduced EBRT was also good. 
The highest grade of transient local toxicity was G3, which occurred in 3/32 pts following the completion of WB-EBRT. The combination 
of IART
®+EBRT was well accepted by the patients, without any changes to their quality of life. 
Conclusions: These preliminary results support the hypothesis that IART
® may represent a valid approach to accelerated WB irradiation 
after BCS. We hope that this nuclear medicine technique will contribute to a better management of breast cancer patients. 
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Introduction 
Breast conserving surgery (BCS) to excise the tumour with 
adequate margins followed by whole-breast external beam 
radiotherapy (WB-EBRT) is now considered the standard 
treatment for the majority of patients with early breast cancer 
[1–3]. 
The post-operative radiotherapy schedule that follows BCS is 
usually delivered in daily fractions each weekday for a period of 
six to eight weeks. This can represent a logistic problem for 
many patients, particularly the elderly and those who reside a 
considerable distance from a radiation treatment facility [4, 5]. 
The radiotherapy schedule currently recommended consists of 
45–50 Gy at 1.8–2 Gy per fraction to the WB, followed by a 10–
16 Gy boost to the tumour bed [6]. 
Based on the results of several prospective randomised clinical 
trials comparing BCS with or without WB-EBRT, locoregional 
recurrence occurs in approximately 10%–35% of women 
receiving BCS alone and in 0.3%–8% of women after BCS plus 
WB-EBRT (follow-up range: 39–102 months) [2, 3]. Although 
the WB-EBRT impact on survival is uncertain, for most patients 
who choose BSC instead of mastectomy, reducing the risk of 
local recurrences matches the therapeutic priorities and 
preferences that motivated their choice of BCS. Nevertheless, 
evidence suggests that up to 30% of patients who undergo BCS 
for early breast cancer did not receive, for some reason, post-
operative breast irradiation. 
As an alternative to conventional WB-EBRT, partial breast 
irradiation (PBI) using intra-operative radiotherapy (IORT) or 
other modalities such as MammoSite, brachytherapy, high-
conformal EBRT have been recently proposed [7–11] and are 
currently under clinical evaluation. As yet, there is no firmly 
established standardised IORT dose for PBI in early breast 
cancer. Although valid, PBI presents two major limitations: (a) 
the availability of dedicated devices such as an intra-operative 
linear accelerator, MammoSite balloon, etc. and (b) a restricted 
field of irradiation, which limits the management of positive 
surgical margins and unsuspected clinical neoplastic foci far 
from the primary tumour. 
Previous experiences in locoregional treatment of peritoneal 
carcinomatosis and malignant gliomas, using 
90Y-Biotin with an 
avidin-based pre-targeting technique [12–14], lead us to 
assume that the application of a radionuclide therapy, with 
radio-labelled biotin, might also represent an alternative 
approach to deliver radiation (beta and alpha particles) to the 
operated breast. We thus developed a new technique named 
IART
®: Intra-operative Avidination for Radionuclide Therapy that 
relies on the avidin–biotin binding system. 
Avidin is a 66 kDa highly glycosylated and positively charged 
(isoelectric point, pI ≅ 10) tetrameric protein, which is extracted 
from the white of the egg, which shows extremely high affinity 
for the 244 Da vitamin, biotin (kd = 10
−15 M). 
Briefly, the ‘avidination’ of the operated breast with native 
avidin, directly injected by the surgeon, into and around the 
tumour bed, provides a target for the radio-labelled biotin 
intravenously [15] injected one day later. 
Furthermore, it is well known that the inflammatory reaction 
displays cation-exchanging properties [16–18]. Thus, at the 
surgical site, avidin is retained for several days, acting as an 
‘interstitial molecular device’ able to bind radio-labelled biotin. 
The proof of the principle of this new approach was documented 
in a biodistribution and pharmacokinetic studies conducted in 
ten patients who underwent BCS. The IART
® dosimetry with 
111In-Dota-biotin according to the Medical Internal Radiation 
Dose MIRD formula and the linear quadratic model (biological 
effective dose, BED) was previously reported [15, 19, 20]. 
We present here the results of a phase I–II study in which 
IART
® was applied to deliver a 20 Gy dose with 
90Y-labelled 
biotin, as an anticipated boost to a shortened EBRT course, in 
women who underwent BCS for breast cancer. 
Primary objectives of this study were:  
(a)  to determine the optimal dose of avidin with a fixed 
activity (3.7 GBq) of 
90Y-ST2210 in order to provide a 
dose of 20 Gy; 
(b)  to assess local and systemic toxicity and to evaluate 
the pharmacokinetics of different amount of avidin. 
A secondary objective was to assess patient’s quality of life 
(QoL), including the cosmetic results, after the combined 
treatment IART
® and reduced EBRT. 
 
Material and methods 
Thirty-five post-menopausal women with breast cancer suitable 
for BCS were enrolled. Inclusion criteria were: age < 75 years; 
diagnosis of breast cancer on the basis of cytology, histology 
and mammography/echography; tumour size < 5cm with 
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Table 1: Three consecutive cohorts of patients treated with different levels of avidin. All patients received
 90Y-ST2210 (3.7 GBq) spiked with 
111In 
(185 MBq) 
clinically negative axillary lymph nodes and absence of distant 
metastases (T1-2, cN0, M0); Karnofsky performance status ≥ 
70%; adequate haematological function: WBC > 3000/mm
3, 
ANC > 2500/mm
3, Hb ≥ 10 g/dl; platelets ≥ 150,000/mm
3; serum 
creatinine < 1.5 × UNL; normal liver function: total bilirubin ≤ 1.5 
× UNL; alkaline phosphatase ≤ 2.5 × UNL and ALAT and/or 
ASAT ≤ 1.5 × UNL. 
Patients with non-infiltrating tumour of the breast, Paget’s 
carcinoma or a non-carcinoma histotype were excluded from 
the protocol. Other exclusion criteria were previous excisional 
biopsy on the same breast, history of neoplasia, insulin-
dependent diabetes mellitus, hypertension not 
pharmacologically controlled, previous treatment with avidin, 
referred allergy to eggs, poor compliance with radiotherapy and 
the follow-up program, concomitant treatment with experimental 
drugs. 
This study was conducted according to the ethical principles, 
which are derived from the Declaration of Helsinki, from the 
Good Clinical Practice guidelines and from applicable 
legislation. The protocol was started after Ethical Committee 
approval (Study Protocol IEO S313/406). 
Before entering the study, each candidate accepted to 
participate in the study by signing the informed consent form. 
From March 2007 to March 2008, 38 post-menopausal women 
were selected. Thirty-five patients were enrolled. Three patients 
were excluded from the study due to inadequate haematological 
function (platelets <150,000/mm
3), abnormal liver function 
(ALAT and ASAT >1.5 x UNL) or the presence of a non-
infiltrating carcinoma. The mean age of the treated patients was 
63 years (range 42–74). 
All patients underwent partial breast resection 
(quadrantectomy). Sentinel node biopsy alone was carried out 
in 28 patients; 7 patients had sentinel node positive and axillary 
dissection followed. Pathological examination demonstrated an 
infiltrating ductal carcinoma in 24 cases, 2 mucinous carcinoma, 
3 infiltrating lobular carcinoma, and an infiltrating tubular 
carcinoma in 1 case, 2 infiltrating mixed carcinoma, 1 infiltrating 
papillary carcinoma; in two patients an intra-epithelial neoplasia 
was diagnosed as DIN1 c, DIN G2, respectively. One patient 
underwent breast reduction for cosmetic purposes after tumour 
removal. All patients received avidin administration in the 
surgical bed as previously described [15, 20]. Briefly, after the 
primary tumour excision, the surgeon injected native avidin 
diluted into 30 ml of saline solution into and around the tumour 
bed, by means of three syringes (10 ml each). Two syringes 
were used for intra-parenchyma injection (every 1.5 cm) and the 
third for the resection margins, after having closed the gland. 
Three consecutive cohorts of patients were treated according to 
the protocol (Table 1). 
The starting dose of avidin (100 mg) was based on the results 
of previous studies [15, 20]. In the present study, the lower 
avidin dose (50 mg) and the higher avidin dose (150 mg) were 
also investigated in order to identify the optimal amount able to 
provide a 20 Gy dose to the tumour area, after a fixed activity of 
90Y-biotin (3.7 GBq). 
After avidin administration (mean time 18 ± 3 h) and before the 
i.v. injection of radioactive biotin, 5,10 or 15 mg (1/10 of the 
avidin dose) of biotinylated human serum albumin (HSA-biot) 
were administered intravenously for 5 min. This biotinylated 
chase was intended to reduce circulating avidin as previously 
described [20]. Thereafter, 3.7 GBq of 
90Y-ST2210 (specific 
activity of 4 GBq/mg) together with 185 MBq of 
111In-biotin 
(specific activity of 4 GBq/mg) was delivered intravenously by 
slow infusion, using a dedicated disposable system [21]. 
 
Imaging, biodistribution and dosimetry 
Total body scintigraphic images were collected after 1.5 ± 0.5, 5 
± 2, 16 ± 4 and 24 ± 6 h after the administration of the radio-
labelled biotin, using a double-head γ-camera (GE, Infinia II)
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To view this video click here:
 
http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2010.166
   
 
Figure: 1 a: SPECT/CT fused images showing a hot region in the operated left breast. b: The hot region was divided into three different areas: 
high-uptake area (uptake higher than 50% of the maximum—isorois 50%); medium-uptake area (between 50% and 30% isorois) and low-uptake 
area (between 30% and 10% isorois).   
equipped with a medium-energy general-purpose collimator 
(MEGP). A SPECT image was acquired after 16 ± 4 h in order 
to provide maps of activity distribution of the index quadrant. A 
low-dose CT was also acquired in order to evaluate the patient-
specific organ masses, especially the kidneys. 
In the diagnostic phase [20], the attention was focused on 
biodistribution, pharmacokinetics and dosimetry in normal 
organs. In this phase I–II study (Study Protocol IEO S313/406),
we focused on dosimetry of the breast region and of the critical 
organs (kidneys). For this purpose, functional images (SPECT) 
have been fused to morphological images (CT), using the 
workstation Advantage Windows (GE Medical System). Before 
SPECT, three radioactive and radio-opaque markers were 
positioned on the skin of the patient to allow appropriate image 
matching. SPECT/CT fused images were used to assess the 
correct tracer localisation in the breast (Figure 1a). 
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Dosimetry was performed as previously described [15]. Time 
activity curves were obtained for the normal organs (whole body 
images) and the breast gland (SPECT and whole body images). 
In particular, the breast region was divided into three different 
areas (Figure 1b). 
(a) High-uptake area (uptake higher than 50% of the 
maximum—isorois 50%); 
(b)  medium-uptake area (between 50% and 30% isorois);  
(c)  low-uptake area (between 30% and 10% isorois). 
For each patient, dose calculations were performed entering the 
number of decays (ND) estimated for normal organs (kidneys, 
heart, lungs, red marrow, urinary bladder contents and 
remainder of the body) and irradiated breast in the 
OLINDA/EXM software [22], applying the correction for the 
individual patient weight and organ masses. In particular, the 
self-dose in the three breast areas were calculated considering 
the ND values derived for the three areas identified (high, 
medium, low uptake), with the approximation of uniform activity 
distribution in lesions (OLINDA/EXM, sphere model). 
Finally, to analyse the differences between the three 
consecutive cohorts of patients, the following parameters 
related to the breast area were compared: 
(a)  maximum uptake (%) of injected activity in the breast 
area; 
(b)  number of decays in the breast area showing high 
uptake; 
(c)  absorbed dose per unit activity in the breast area 
showing high uptake. 
 
Biological effective dose: the linear 
quadratic model 
The linear quadratic model enabled the comparison of doses 
released through EBRT to those from IART
® for the analysis of 
possible effects on the operated breast and non-target organs. 
In particular, we adopted the BED expression defined by [19]: 
1/2 rep 2
1/2 rep 1/2 eff
1
BED
/
T
DD
TT αβ
⎛⎞
=+ × ⎜⎟ ⎜⎟ + ⎝⎠
, 
where D is the dose delivered, T1/2 rep is the repair half-time of 
sublethal damage and T1/2eff is the effective half-life of the
radiopharmaceutical in the specific tissue. The α/β ratio relates 
the intrinsic radiosensitivity (α) and the potential sparing 
capacity (β) for a specified tissue or effect. For the breast 
region, we used a T1/2 rep equal to 1.5 h, α/β 10 Gy; for the 
kidneys, we used a T1/2 rep equal to 2.8 h, α/β 2.6 Gy [20, 23, 
24]. 
 
Radiation therapy 
Post-operative external-beam radiation was delivered to the 
entire breast four weeks after IART
®. Patients were treated in 
the supine position, placed on a breast board, with both arms 
raised above head. A 6-MV photon intensity was used to deliver 
a dose of 40 Gy: 2.0 Gy, fractions for five days/week for four 
weeks, with an isocentric technique. The target volume was the 
entire breast parenchyma, extending from 5 mm below the skin 
surface to the deep fascia, excluding the underlying muscle and 
rib cage. The tangential technique using a parallel pair of 
radiation beams angled anteriorly to produce coplanar posterior 
field edges was employed. The breast was included in the 95% 
isodose line and the dose maximum was documented on the 
treatment plan. Wedges and appropriate shielding were used 
and dose-volume histograms for organs at risk were plotted. 
 
Results 
The WBS images (Figure 2) showed a fast and intense uptake 
of the radio-labelled biotin in the breast area of all patients. 
Dosimetric data and estimated masses of the irradiated breast, 
obtained for the three cohorts of patients, showed that a 
considerable mass of breast parenchyma, with a mean value of 
250 g, was irradiated using 100 or 150 mg of avidin.  Data from 
the 15 women, given 100 mg of avidin, showed a mean 
absorbed dose to the breast of 19.5±4.0 Gy in the area of 
highest uptake, with a corresponding BED of 21.2±4.3 Gy. The 
dose of 100 mg of avidin resulted to be the most appropriate 
(and the minimum needed) in terms of dose delivery into the 
index quadrant. The gap between surgery and biotin injection 
did not influence the percentage uptake in the operated breast, 
which reached 12% with a mean value of ∼ 8% (see Table 2).  
The absorbed dose to the kidneys after injection of 3.7 GBq of 
90Y-DOTA-biotin was 3.8 ± 1.1 Gy (1.0 ± 0.3 Gy/GBq), 
comparable with the results obtained in the previous study (1.2 
± 0.4 Gy/GBq) [15]. Moreover, the estimated BED for the 
kidneys was 4.3+1.7 Gy, well below the 44 Gy reported in the 
literature as the TD50/5 for renal damage [24]. The absorbed 
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Table 2: Dosimetric data (mean values ± SD) of the high-, medium- and low-uptake areas of the irradiated breast  
 
 
 
Figure 2: Whole body scans (anterior projection) acquired at 1, 3, 15 and 24 h post-injection of 
90Y-biotin in a patient operated in the right 
breast.
dose to the red marrow was 0.2 ± 0.1 Gy, never exceeding 0.4 
Gy, giving no concern for haematological toxicity. 
 
Toxicity and quality of life 
No side effects were observed after avidin administration and 
biotinylated HSA chase, nor after radio-labelled biotin, either 
111In or 
90Y labelled. Systemic toxicity, assessed by evaluating 
haematological, liver and renal functions, was not found. The 
overall cosmetic result was good. 
Thirty-five patients received IART
® and 32 completed EBRT, 
starting four weeks after IART
®. In one case, due to the 
presence of sieroma on the tumour bed, EBTR started one 
week later. In one patient, the course of EBRT was extended 
through two months instead of one month: the treatment was
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Table 3: Local toxicity in 35 patients at different time points (post-IART, during EBRT, one month and six months after EBRT) evaluated by 
RTOG Scale 
 
Figure 3: Good cosmetic results and normal wound healing in a patient who received IART
® alone. 
stopped for four weeks due to inflammation and then restarted 
when the process had resolved. One patient, who underwent 
cosmetic bilateral breast plastic reconstructive surgery, 
developed a bilateral delay to wound healing and so WB-EBRT 
commenced two months after IART
®. Three patients did not 
receive EBRT: one patient underwent nipple-sparing 
mastectomy because of positive margins of resection after 
quadrantectomy; in two patients the definitive histological 
examination showed low-grade intra-epithelial neoplasia. The 
cosmetic result and wound healing of one of these patients is 
shown in Figure 3. 
The compliance to EBRT and local toxicity during treatment at 
the one- and six-month follow-ups were assessed by evaluating 
local signs according to the Radiation Therapy Oncology Group 
(RTOG) Scale. The presence of symptoms (pain, itch and 
burning) was reported at each clinical control. Patients were 
controlled at the weekly EBRT sessions. All the 32 patients 
reported mild pain or/and itch in correspondence to the surgical 
bed during and at the end of the treatment. These symptoms 
resolved within one week after the end of EBRT. Table 3 reports 
the local toxicity results in the 32 patients who received EBRT 
after IART
®.  The majority of patients experienced low-grade
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Table 4: Average quality-of-life score (EORTC QOL-30 questionnaire) at various times during treatment and follow-up for global functions. A 
low score (minimum 0) indicates poor quality of life and a high score (maximum 100) indicates good quality of life 
 
 
Figure 4: Patient who received IART
® plus EBRT. a: No local toxicity was observed  four weeks after IART
®; b: mild local toxicity after delivery 
of 20 Gy by EBRT; c: local toxicity (classified as G1) month after completion of EBRT; d: no local toxicity present six months after EBRT. 
Cosmetic outcome was judged good. 
toxicity during EBRT, starting from the second week. At the end 
of EBRT, local toxicity was classified as G2 in 25 patients and 
as G1 in 4 patients. Grade 3 skin toxicity was observed in three 
patients. Four weeks after the completion of WB-EBRT, no local 
toxicity (G0) was observed in 20 cases, while 10 patients had 
residual G1 and 2 patients had G2 toxicity. All patients 
completed the six-month follow-up and showed an excellent 
tolerance to the whole treatment schedule. Figure 4 depicts an 
example of mild local toxicity through the time, with a complete 
recovery six months after EBRT treatment. 
Six patients underwent chemotherapy: three patients received 
an anthracycline and CMF scheme (cyclophosphamide, 
methotrexate and fluorouracil), one patient received CMF alone, 
one patient received vinorelbine plus Trastuzumab and the last 
one anthracycline plus Trastuzumab and letrozole. All patients 
started chemotherapy at the completion of the EBRT. The 
remaining 29 patients had positive hormonal receptor status 
and were given endocrine therapy. No significantly delayed 
toxicity was observed in the six subjects who received 
chemotherapy. 
IART
® plus short four-week EBRT treatment was very well 
accepted by the patients. The quality of life, evaluated by the 
EORTC QoL questionnaire, demonstrated no significant 
changes in patients’ quality of life (Tables 4 and 5). 
 
Discussion 
The results of this pilot study suggest that the IART
® is a safe 
nuclear medicine procedure able to deliver, one day after 
surgery, a 20-Gy radiation dose to women who underwent BCS 
for breast cancer. 
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Table 5: Average quality-of-life score (EORTC QOL-30 questionnaire) at various times during treatment and follow-up for symptoms. A low 
score (minimum 0) indicates good quality of life and a high score (maximum 100) indicates poor quality of life
The minimum quantity of avidin that reliably provides the 20-Gy 
target dose is 100 mg; 50 mg provides a slightly lower dose, 
while 150 mg does not appreciably increase it. The dose of 100 
mg of avidin acts as an ‘interstitial molecular device’ that 
specifically binds 
90Y-labelled-DOTA-biotin in a considerable 
mass of breast tissue, without any significant side effects. 
IART
® takes advantage of the high affinity between avidin and 
biotin and mimics the well-known model of radiometabolic 
treatment with 
131I in differentiated thyroid carcinoma. 
The scintigraphic images demonstrated a fast and stable uptake 
of labelled 
90Y-DOTA-biotin at the operated breast site. 
Moreover, in 20 patients, the axillary lymph nodes or the internal 
mammary chain nodes were visualised. This observation 
indicates that avidin, as albumin colloids for the sentinel node 
biopsy, is drained into the blood stream through the lymphatic 
system and so lymph-node irradiation with IART
® would also be 
possible. 
The rapid renal elimination of labelled DOTA-biotin is important 
for the radiation protection point of view, allowing a short period 
of hospitalisation (ideally one day). 
IART
® could be an interesting nuclear medicine procedure for 
breast irradiation similar to the other techniques of partial breast 
irradiation, but offering many practical advantages over other 
methods. 
One of the main advantages is its potential applicability to every 
kind of breast cancer patient scheduled for conserving surgery, 
without limitations of tumour location and size or multifocality.
Importantly, with IART
®, the irradiation field is identified with 
precision by the surgeon, who knows exactly where the tumour 
was located and therefore injects avidin under visual control 
directly into the tumour bed, thus preparing the remaining 
mammary gland to receive 
90Y-biotin. With a surgeon of 
average experience, avidin injection around the tumour bed 
should be simple and uniform throughout the target area of the 
breast. Another IART
® advantage is that neither dedicated 
linear accelerator nor other sophisticated devices are needed. 
IART
® is a procedure that may be applied worldwide in all 
hospitals where breast surgery is performed and a nuclear 
medicine unit is present. Moreover, the possibility to inject 
90Y-
radio-labelled biotin 16–24 h after avidin administration makes 
the procedure suitable even if the nuclear medicine department 
is not close to the surgical unit. A future possible clinical 
scenario could be the production of 
90Y-radio-labelled biotin in a 
GMP central radio pharmacy and delivered within few hours to 
the surrounding hospitals. This should facilitate a worldwide use 
of BCS and accelerated radiotherapy especially when logistical 
barriers to travelling are present, with consequent rebound on 
both the patient’s quality of life and socioeconomic aspects.  
A short learning curve would be required for the team 
(surgeons, radiotherapists and nuclear medicine physicians), 
and in our opinion, five-to-ten procedures are a suitable number 
to ensure a good degree of self-confidence with this approach. 
A possible disadvantage of this technique could be an 
inhomogeneous distribution of the radiopharmaceutical, as a 
direct consequence of the surgeon’s poor attention during the
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Figure 5: a: A multi-hole needle conceived in order to deliver avidin at different depths into the breast parenchyma at each injection site. b: A 
screw syringe designed to deliver an equal volume (0.7 ml) of avidin in the surgical bed.
avidin injection. As a consequence, the areas of breast 
parenchyma, which receive more avidin, may be more 
irradiated, although the overnight gap between avidin and biotin 
injection should equilibrate the avidin tissue concentration. In 
order to overcome this possible negative aspect, a special multi-
hole needle (Figure 5), attached to a screw syringe (Figure 5b), 
has been investigated by our group. These devices should 
ensure the administration, at different depths, of an equal 
defined volume of avidin into each injection site. Moreover, in 
order to evaluate the distribution homogeneity of 
90Y-biotin, we 
also calculated the equivalent uniform dose (EUD) to the target 
area, applying voxel dosimetry. The EUD/BED ratio in the 
targeted tissue resulted to be 0.91. This value, obtained due to 
the crossfire effect of 
90Y-biotin, indicates a biological efficacy 
comparable to that of uniform dose distribution. 
Regarding the amount of radio-labelled biotin injected, we may 
increase the specific activity of 
90Y-DOTA-biotin (30–40 
GBq/mg), so that increasing  the dose to the target breast and 
reducing the amount of injected activity.  This is demonstrated 
by a previous study [25], which confirmed that high 
radiochemical purity (>99%) was routinely achieved with 
90Y-
DOTA-biotin prepared at the specific activities used in this study 
and even at tenfold higher levels (up to 40 GBq/mg). In the 
future, using higher specific activities of 
90Y-biotin-DOTA, it is 
likely that the kidneys, bone marrow and whole body doses can 
be further reduced by 10%–20%. This can be aim of future 
investigations. 
Moreover, as for IORT plus EBRT [26], adopting a treatment 
protocol of IART
® followed by 14 sessions of EBRT (spread 
over 2.5 weeks), a patient can save about 50% of the time 
required either by standard EBRT + a final boost (normally 
provided in 25–30 radiotherapy sessions spread over five to six 
weeks), or by the other accelerated radiotherapy schemes 
(normally spread over approximately five weeks) [27].  In 
addition, the scheme for IORT + EBRT is very similar to the 
combined IART
®+EBRT protocol; however, a dedicated linear 
accelerator (or other sophisticated devices) are not required, so 
the procedure can be carried out wherever a nuclear medicine 
unit is present. This would facilitate a wider use of conservative 
breast surgery followed by post-operative radiotherapy. 
The value of the boost has been demonstrated by studies like 
the ‘EORTC boost versus no-boost trial’ [28, 29], which has 
shown that patients who did not receive an electron boost to the 
tumour bed may have a worse clinical outcome than patients 
who received such a boost. 
Moreover, an anticipated boost may entail a shortened gap 
between surgical removal of the tumour and the start of 
radiotherapy. This is considered crucial to prevent repopulation 
from neoplastic cellular clones present in microscopic residual 
disease. Indeed, after surgery, an ‘accelerated repopulation’ 
may occur, with an early phase in which neoplastic cells grow in 
an exponential way. The delivery of a boost of radiation 
immediately after surgery may avoid such a process and is 
discussed below. 
Several studies support the rationale of intra-operative radiation 
therapy (RT) as an adjuvant therapy after surgery, including 
systematic reviews [30]. Specifically, a short time interval 
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between surgery and RT should increase the probability of local 
tumour control [31]. An analysis of the surviving fraction (SF) 
and the tumour control probability (TCP), evaluated after 
different schemes of radiation delivery to breast cancer cells, 
show a decrease of the SF and an increase of the TCP when 
intra-operative radiation techniques are used, as compared to 
the standard EBRT alone. 
Conclusions 
In March 2008, the study has been concluded with 38 patients 
enrolled. Thirty-five patients were evaluated. No side effects 
were observed after avidin administration and 
90Y-biotin 
infusion. The dose of 100 mg of avidin resulted to be 
appropriate in order to deliver the radiation dose required (19.5 
± 4.0 Gy), corresponding to a BED of 21.2 ± 4.3 Gy to the 
surgical bed. The absorbed dose to the kidney was 3.8 ± 1.1 
Gy, and no haematological toxicity was observed. 
At the end of IART
® treatment, no local toxicity occurred and the 
overall cosmetic result was good. Thirty-two patients completed 
EBRT. The tolerance to EBRT was good with no significant 
difference from conventional treatment. IART
® was well 
accepted by all patients; it did not involve any changes in their
quality of life. Based on these preliminary data, it seems that the 
entire IART
®-EBRT procedure is generally well tolerated, with 
few cases of temporary local toxicity. 
IART
® can be considered as an ‘anticipated boost’ three to four 
weeks before WB irradiation with EBRT. This will turn out in a 
new approach for accelerated WB irradiation after BCS, with 
considerable economical and social impact. As for sentinel node 
lympho-scintigraphy and biopsy [32, 33], we hope that this 
nuclear medicine technique will contribute to a better 
management of breast cancer patients. 
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